Want to see HK:2297 full AI Analyst Report?
2297 Stock Chart & Stats
HK$0.26
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$0.26
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.18 - HK$0.40
Previous CloseN/A
Volume40.00K
Average Volume (3M)114.77K
Market Cap
HK$269.06M
Enterprise ValueHK$374.62
Total Cash (Recent Filing)HK$153.35M
Total Debt (Recent Filing)HK$24.83M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding1,401,358,800
10 Day Avg. Volume54,100
30 Day Avg. Volume114,766
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.88
Price to Sales (P/S)16.34
P/FCF Ratio-3.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recurring Consumables ModelProcedure-linked consumables can generate repeat hospital purchasing alongside device sales, giving the business a potentially recurring revenue base and a path to deeper customer relationships as product adoption expands.
Conservative LeverageLow leverage provides greater financial flexibility than a debt-heavy structure and may reduce near-term solvency pressure while management works to restore profitability, although ongoing losses could still weaken the balance sheet.
Reduced Cash BurnThe improvement in cash burn suggests some progress in controlling cash outflows and limits the pace of balance-sheet depletion relative to prior years, creating more time for operational recovery despite continued funding needs.
Bears Say
Sharp Revenue ContractionTwo consecutive years of substantial revenue contraction indicate weak commercial traction or reduced demand and limit operating scale, making it harder for fixed costs, product investment, and sales infrastructure to be absorbed.
Negative Product EconomicsNegative gross margin means current product sales do not cover direct costs, a fundamental deterioration that threatens the viability of the operating model and requires meaningful pricing, manufacturing, or product-mix improvement.
Persistent Cash-flow DependenceContinued operating and free-cash-flow deficits show that the company has not achieved self-funding capability, increasing reliance on existing balance-sheet resources or external financing to sustain operations and investment.
Rainmed Medical Limited News
2297 FAQ
What was Rainmed Medical Limited’s price range in the past 12 months?
Rainmed Medical Limited lowest stock price was HK$0.18 and its highest was HK$0.40 in the past 12 months.
What is Rainmed Medical Limited’s market cap?
Rainmed Medical Limited’s market cap is HK$269.06M.
When is Rainmed Medical Limited’s upcoming earnings report date?
Rainmed Medical Limited’s upcoming earnings report date is Apr 01, 2027 which is in 207 days.
How were Rainmed Medical Limited’s earnings last quarter?
Rainmed Medical Limited released its earnings results on Aug 31, 2026. The company reported -HK$0.019 earnings per share for the quarter.
Is Rainmed Medical Limited overvalued?
According to Wall Street analysts Rainmed Medical Limited’s price is currently Overvalued.
Does Rainmed Medical Limited pay dividends?
Rainmed Medical Limited does not currently pay dividends.
What is Rainmed Medical Limited’s EPS estimate?
Rainmed Medical Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rainmed Medical Limited have?
Rainmed Medical Limited has 1,401,358,800 shares outstanding.
What happened to Rainmed Medical Limited’s price movement after its last earnings report?
Rainmed Medical Limited reported an EPS of -HK$0.019 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Rainmed Medical Limited?
Currently, no hedge funds are holding shares in HK:2297
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rainmed Medical Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
18.99%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Rainmed Medical Limited
Rainmed Medical Limited is a medical technology firm specializing in the creation, development, and market launch of advanced systems that utilize coronary angiography to assess fractional flow reserve (FFR) and the index of microvascular resistance (IMR). Its offerings include the FlashAngio caFFR System, which accurately determines FFR values by reconstructing a three-dimensional model of the coronary arterial system from two angiographic images. Additionally, the company provides the FlashAngio caIMR System, an innovative non-invasive solution for the diagnosis and treatment of microcirculatory lesions. Rainmed Medical is also engaged in pioneering intelligent angiographic injection technologies, robotic navigation systems for vascular interventions, and flash renal denervation solutions. Established in 2014, the company is headquartered in Suzhou, China.
Technical Analysis
Acotec Scientific Holdings Limited
―
Vincent Medical Holdings Limited
―
Broncus Holding Corp.
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―
Venus Medtech (Hangzhou), Inc. Class H
―